High materiality9/10
B.Riley Reiterates Buy Rating on Spruce Biosciences, Inc. (SPRB)
Why it may matterVerify against the original reporting
Bullish upside remains.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
B.Riley Financial reiterates Buy on SPRB with a target of $160; current price around $45.71.
- B.Riley maintains Buy; target $160; price $45.71.
Key facts
- 01
Target: $160
- 02
Posted price: $45.71
- 03
Analyst firm: B.Riley Financial
- 04
Analyst: Madison El-Saadi
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.